794 | PATIENT‐REPORTED ADVERSE EVENTS AND HEALTH‐RELATED QUALITY OF LIFE BY CAR T‐CELL PRODUCT IN PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMAS

Le résumé fourni par la source

ROR 0.53, CI 0.4-0.6 respectively), when compared to glofitamab.Given three approved CAR-Ts, reporting odds ratios were calculated for each pair.There was no difference in death associated with disease progression when comparing Tisa-cel to Liso-cel.Axi-cel had fewer relative reports of death when compared to Liso-cel (ROR 0.3, CI 0.24-0.37),with no difference in reports of death without associated progression.Tisa-cel had more reports of death associated with disease progression compared to Axi-cel (ROR 2.34, CI 1.18-4.68),but was not significant for death without progression.While there are limitations of using FAERS that restrict the conclusion of causality due to reporting bias, this data demonstrates there are important toxicities that can inform treatment team's decisions.Further comparison of post-market data to existing randomized control trials will help further identify new adverse events, or elucidate existing under-or over-reported events.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.